Overview
Xiao-bin Zheng practices practicing medicine in Guangzhou, China.
Their clinical expertise encompasses Colorectal Cancer, Viral Gastroenteritis, Colitis, and Crohn's Disease.
They are actively involved in clinical research, co-authoring 15 peer reviewed articles.
Locations
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
Frequently Asked Questions about Xiao-bin Zheng
Is Xiao-bin Zheng a top-rated expert for Colorectal Cancer?
MediFind is an objective health platform that identifies experts based on real-world data. Xiao-bin Zheng is classified as an Experienced expert for Colorectal Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.
Does Xiao-bin Zheng participate in research or clinical trials?
Yes. Xiao-bin Zheng has published 15 articles and abstracts on conditions like Colorectal Cancer. You can view a list of Xiao-bin Zheng's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Experienced
- ColitisZheng isExperienced. Learn about Colitis.
- Colorectal CancerZheng isExperienced. Learn about Colorectal Cancer.
- Crohn's DiseaseZheng isExperienced. Learn about Crohn's Disease.
- Viral GastroenteritisZheng isExperienced. Learn about Viral Gastroenteritis.